ClinicalTrials.gg
Not yet recruitingNCT05727241Updated Apr 25, 2023

Three-dimensional Umbilical Cord Coiling Index

An observational study in Umbilical Cord Issue, Intrauterine Growth Restriction and Fetal Distress, sponsored by Western Galilee Hospital-Nahariya. Not yet recruiting at 1 site in Israel. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-25.

Sponsored by Western Galilee Hospital-Nahariya · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Previous studies have shown that abnormal coiling of the umbilical cord is associated with adverse perinatal outcome. For example, an umbilical cord that is non-coiled increases the chance of fetal morbidity and mortality, moreover, they have shown that the lack of the usual coiled umbilical cord configuration may result in an umbilical cord that is structurally less able to withstand external mechanical stress, on the other hand, studies from recent years show that hypercoiling - excessive coiling of the umbilical cord is associated with poor obstetric outcomes, such as fetal distress at birth, meconium staining, fetal acidosis, premature birth, intrauterine growth disorder and even fetal death.

The studies carried out on the calculation of UCI include performing these measurements in two dimensions, including Doppler activation, but no studies were carried out in which three dimensions were used. The purpose of the study is to measure UCI using a 3D method in a random sample of 250 patients beyond 24 week of gestation, and to compare pregnancies with hypercoiling, hypocoiling or with a normal number of coils in terms of birth outcomes.

Read the detailed description

The umbilical cord connects the growing fetus to the placenta and contains 3 blood vessels, 2 arteries and a vein. The umbilical cord is protected by a layer of Wharton jelly and is characterized by being coiled. This coiling provides the umbilical cord with strength and flexibility simultaneously, and as a result lowers the risk of complications such as torsion of the umbilical cord.

The reason for the formation of this coiling is unknown, but there are many hypotheses such as mobility and rotation of the fetus around the axis of the umbilical cord, a different growth pattern of the blood vessels in the umbilical cord and a special arrangement of the muscles in the walls of the arteries of the umbilical cord.

Umbilical cord index (UCI) is the distance between one coil of the umbilical cord. it is calculated from the inner edge of the wall of an umbilical cord artery or vein to the outer edge of the same vessel in the next coil, the direction is from the edge of the placenta to the fetus. The final value is the average of three readings in three different segments of the umbilical cord.

Previous studies have shown that abnormal coiling of the umbilical cord is associated with adverse perinatal outcome. For example, an umbilical cord that is non-coiled increases the chance of fetal morbidity and mortality, moreover, they have shown that the lack of the usual coiled umbilical cord configuration may result in an umbilical cord that is structurally less able to withstand external mechanical stress, on the other hand, studies from recent years show that hypercoiling - excessive coiling of the umbilical cord is associated with poor obstetric outcomes, such as fetal distress at birth, meconium staining, fetal acidosis, premature birth, intrauterine growth disorder and even fetal death.

The studies carried out on the calculation of UCI include performing these measurements in two dimensions, including Doppler activation, but no studies were carried out in which three dimensions were used. The purpose of the study is to measure UCI using a 3D method in a random sample of 250 patients beyond 24 week of gestation, and to compare pregnancies with hypercoiling, hypocoiling or with a normal number of coils in terms of birth outcomes.

02

Conditions studied

  • Umbilical Cord Issue
  • Intrauterine Growth Restriction
  • Fetal Distress

Keywords

  • Coiling index
  • Neonatal outcome
  • Intrauterine Growth Restriction
  • Antepartum screening
03

In context

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

This study's planned enrollment of 250 is above the median of 200 across 145 observational studies indexed under Fetal Growth Retardation.

Browse Fetal Growth Retardation studies →

Lead sponsor

Western Galilee Hospital-Nahariya is the lead sponsor of 89 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will include low-risk singleton pregnancies, above 24 weeks of pregnancy, women with normal anatomical scan results and normal aneuploidy screening results. Women who have polyhydramnios, Oligohydramnios or intrauterine growth restriction at the time of recruitment will be ruled out.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton pregnancy
  • Pregnancy week > or = 24.0

Exclusion criteria

Exclusion Criteria:

  • Twin pregnancy
  • Pregnancy week\<24
  • Single umbilical cord
  • Insufficient prenatal care
  • Abnormal anatomical fetal findings, abnormal results of aneuploidy screening
  • Premature rupture of membranes
  • Polyhydramnios or Oligohydramnios at the time of recruitment.
  • Intrauterine growth restriction at the time of recruitment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • The study cohort (total sample)

    All women will undergo ultrasound examination for three-dimensional umbilical cord index.

    Diagnostic Test: Ultrasound

Interventions

  • Diagnostic testUltrasound

    The intervention is ultrasound examination with three dimensional umbilical cord index, two-dimensional umbilical cord index, and doppler examination of the umbilical cord artery.

06

What researchers measure

Primary outcomes

  1. Intrauterine growth restriction

    The correlation between three-dimensional umbilical cord index and the rate of intrauterine growth restriction

    Time frame: 1 year

Secondary outcomes

  1. Two-dimensional umbilical cord index

    The correlation between three-dimensional umbilical cord index and the two-dimensional umbilical cord index

    Time frame: 1 year

  2. Doppler index of the umbilical cord

    The correlation between three-dimensional umbilical cord index and the doppler index of the umbilical cord

    Time frame: 1 year

  3. fetal distress during delivery

    The correlation between three-dimensional umbilical cord index and the rate of fetal distress during delivery

    Time frame: 2 years

  4. Meconium staining

    The correlation between three-dimensional umbilical cord index and meconium staining at delivery

    Time frame: 2 years

  5. Delivery mode

    The correlation between three-dimensional umbilical cord index and the delivery mode

    Time frame: 2 years

  6. Cord pH

    The correlation between three-dimensional umbilical cord index and Cord pH

    Time frame: 2 years

  7. APGAR score

    The correlation between three-dimensional umbilical cord index and APGAR score

    Time frame: 2 years

  8. Newborn intensive care unit admission

    The correlation between three-dimensional umbilical cord index and admission to NICU

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Chitra T, Sushanth YS, Raghavan S. Umbilical coiling index as a marker of perinatal outcome: an analytical study. Obstet Gynecol Int. 2012;2012:213689. doi: 10.1155/2012/213689. Epub 2012 Feb 14. PubMed 22496697 ↗
  • Ma'ayeh M, McClennen E, Chamchad D, Geary M, Brest N, Gerson A. Hypercoiling of the umbilical cord in uncomplicated singleton pregnancies. J Perinat Med. 2018 Aug 28;46(6):593-598. doi: 10.1515/jpm-2017-0034. PubMed 28672757 ↗
  • Strong TH Jr, Elliott JP, Radin TG. Non-coiled umbilical blood vessels: a new marker for the fetus at risk. Obstet Gynecol. 1993 Mar;81(3):409-11. PubMed 8437796 ↗
  • Degani S, Lewinsky RM, Berger H, Spiegel D. Sonographic estimation of umbilical coiling index and correlation with Doppler flow characteristics. Obstet Gynecol. 1995 Dec;86(6):990-3. doi: 10.1016/0029-7844(95)00307-d. PubMed 7501354 ↗
  • Sharma B, Bhardwaj N, Gupta S, Gupta PK, Verma A, Malviya K. Association of umbilical coiling index by colour Doppler ultrasonography at 18-22 weeks of gestation and perinatal outcome. J Obstet Gynaecol India. 2012 Dec;62(6):650-4. doi: 10.1007/s13224-012-0230-0. Epub 2012 Aug 17. PubMed 24293842 ↗
  • Rana J, Ebert GA, Kappy KA. Adverse perinatal outcome in patients with an abnormal umbilical coiling index. Obstet Gynecol. 1995 Apr;85(4):573-7. doi: 10.1016/0029-7844(94)00435-G. PubMed 7898836 ↗
  • Machin GA, Ackerman J, Gilbert-Barness E. Abnormal umbilical cord coiling is associated with adverse perinatal outcomes. Pediatr Dev Pathol. 2000 Sep-Oct;3(5):462-71. doi: 10.1007/s100240010103. PubMed 10890931 ↗
  • de Laat MW, Franx A, van Alderen ED, Nikkels PG, Visser GH. The umbilical coiling index, a review of the literature. J Matern Fetal Neonatal Med. 2005 Feb;17(2):93-100. doi: 10.1080/14767050400028899. PubMed 16076615 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2023; primary completion for Mar 2024, 8 months later.

Of 72 non-industry observational studies under Fetal Growth Retardation, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 8 months is below that.

Counting every sponsor, half of 73 studies reached it within 52 months; a quarter within 24 and three quarters within 170.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2023
First posted
Feb 14, 2023
StartEst.
Jul 1, 2023
Primary completionEst.
Mar 1, 2024
CompletionEst.
Mar 1, 2026
Last update
Apr 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727241
Lead sponsor
Western Galilee Hospital-Nahariya
Responsible party
Dr Raneen Abu Shqara (Doctor, Western Galilee Hospital-Nahariya) — Principal investigator
First posted
Feb 14, 2023
Start date
Jul 1, 2023 (estimated)
Primary completion
Mar 1, 2024 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Apr 25, 2023

Study contacts

Raneen Abu Shqara, MD
Contact
rabushqara@gmail.com
+972549793591
Marwan Odeh, MD
Contact
marwano@gmc.gov.il
+972507887486
Marwan Odeh, MD
principal investigator · Galilee Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion